Status: Not yet recruiting
A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors
This is a single-arm, phase II study to evaluate the efficacy and safety of Sacituzumab Tirumotecan, a TROP2-directed antibody-drug conjugate, in patients with advanced thymic epithelial tumors who have received second-line or later therapy.
Participants needed: 38
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Jan 15, 2026
Eligibility criteria
Advanced (unresectable or metastatic) thymic epithelial tumor confirmed by histo... [+10]
Previously received targeted drug therapy with Lucasatuzumab. [+16]